Stroke RSS Page 10

Filtered By:
Condition: Thrombosis
Drug: Pradaxa

This page shows you your search results in order of relevance. This is page number 10.

Order by Relevance | Date

Total 508 results found since Jan 2013.

Dabigatran and Acute Coronary Syndromes
There has been considerable interest in the utility of newer oral anticoagulants for the secondary prevention of myocardial infarction (MI) and acute coronary syndromes (ACS). The direct thrombin inhibitor dabigatran has been approved for stroke prevention in patients with atrial fibrillation. However, as Verheugt discussed, when combined with dual antiplatelet therapy for secondary prevention in patients with ACS, no difference was found between the placebo and dabigatran groups for the composite end point of cardiovascular death, nonfatal MI, or stroke. However, it should also be noted that recent reports have actually ...
Source: The American Journal of Cardiology - May 1, 2013 Category: Cardiology Authors: John R. Kapoor Tags: Readers' Comments Source Type: research

Adherence and outcomes of patients treated with dabigatran: Pharmacist-managed anticoagulation clinic versus usual care.
CONCLUSION: VA patients treated with dabigatran for nonvalvular atrial fibrillation or flutter and followed by a pharmacist-managed ACC did not differ significantly from similar patients receiving UC in the proportion adherent with dabigatran therapy or in the frequency of minor or major bleeding episodes. Thromboembolic events and strokes were absent in both groups. PMID: 23784163 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - June 21, 2013 Category: Drugs & Pharmacology Authors: Lee PY, Han SY, Miyahara RK Tags: Am J Health Syst Pharm Source Type: research

New oral anticoagulants in elderly patients
The new oral anticoagulants (NOACs) dabigatran etexilate, rivaroxaban, and apixaban have been extensively studied for prevention and treatment of venous thromboembolic disease and for stroke prevention in atrial fibrillation. Elderly patients have the highest incidence of thrombotic complications but also have the highest risk of anticoagulant associated bleeding. In this review we critically examine the balance between risks and benefits of NOACs compared with vitamin K antagonists in elderly patients enrolled in phase 3 randomized controlled trials for the management of venous thrombosis and stroke prevention in atrial f...
Source: Best Practice and Research. Clinical Haematology - June 1, 2013 Category: Hematology Authors: Stefano Barco, Yuk Wah Cheung, John W. Eikelboom, Michiel Coppens Source Type: research

The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature
Conclusion: Considering their pharmacological properties, their efficacy and bleeding complications, the new oral agents offer a net favourable clinical profile in orthopedic surgery, atrial fibrillation, acute coronary syndrome and increase the risk of bleeding in critically ill patients. Further studies are necessary to determine the long term safety and to identify the specific reversal agents of these new drugs.
Source: Thrombosis Journal - September 3, 2013 Category: Hematology Authors: Faryal TahirHaris RiazTalha RiazMaaz BadshahIrbaz RiazAmeer HamzaHafsa Mohiuddin Source Type: research

Severe thrombosis of bioprosthesis mitral valve after dabigatran.
Abstract A 41-year-old female was admitted to our hospital with an unidentified source of fever, dyspnea and dizziness. Transthoracic echocardiography demonstrated severe mitral valve regurgitation, and further examination with transesophageal echocardiography (TEE) revealed a 7 mm vegetation on the anterior mitral leaflet. Blood cultures were negative, and after 45 days of empiric 12 g/day ampicillin-sulbactam therapy, the vegetation was shown to have disappeared. However, due to ongoing severe mitral regurgitation and valve deformity, a prosthetic metallic mitral valve replacement was performed. After the operat...
Source: Turk Kardiyoloji Dernegi arsivi - September 1, 2013 Category: Cardiology Authors: Akgüllü C, Eryılmaz U, Kurtoğlu T Tags: Turk Kardiyol Dern Ars Source Type: research

The Efficacy and Safety of Oral Anticoagulants in Warfarin-Suitable Patients With Nonvalvular Atrial Fibrillation: Systematic Review and Meta-Analysis
The novel oral anticoagulants (NOACs) apixaban, dabigatran, and rivaroxaban have been recently indicated for stroke prevention in patients with atrial fibrillation (AF) . Due to a lack of direct head-to-head trials comparing the NOACs, the current systematic review and network meta-analysis (NMA) were conducted to assess their relative efficacy and safety. Three phase III randomized controlled trials enrolling 50 578 patients were included. Results of the NMA show a clear trend favoring NOACs over warfarin with regard to the key outcomes of stroke/systemic embolism and all-cause mortality, with apixaban also showing a...
Source: Clinical and Applied Thrombosis/Hemostasis - November 14, 2013 Category: Hematology Authors: Mitchell, S. A., Simon, T. A., Raza, S., Jakouloff, D., Orme, M. E., Lockhart, I., Drost, P. Tags: Original Articles Source Type: research

Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.
In conclusion, this post-hoc simulation of dabigatran usage based on RE-LY trial dataset indicates that "EU label simulated dabigatran treatment" may be associated with superior efficacy and safety compared to warfarin, and are in support of the EU label and the 2012 European Society of Cardiology AF guideline recommendations. Thus, adherence to European label/guideline use results in a clinically relevant benefit for dabigatran over warfarin, for both efficacy and safety. PMID: 24326736 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 11, 2013 Category: Hematology Authors: Lip GY, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S Tags: Thromb Haemost Source Type: research

There is a need for independent studies about new oral anticoagulants in atrial fibrillation patients
Dabigatran, rivaroxaban, and apixaban are new oral anticoagulants (NOAC) which have been investigated in patients with atrial fibrillation (AF) for primary and secondary prevention of stroke and thromboembolism . In RELY, ROCKET-AF and ARISTOTLE, NOAC had a similar efficacy and safety profile like vitamin-K-antagonists (VKA). Based on these results, NOAC are recommended by national and international societies as an alternative to VKA or even the first choice drug for the prevention of stroke or embolism in AF-patients.
Source: International Journal of Cardiology - January 21, 2014 Category: Cardiology Authors: Claudia Stöllberger, Birke Schneider, Josef Finsterer Tags: Online Letters to the Editor Source Type: research

Perioperative management and therapy of bleeding complications.
Abstract The new oral anticoagulants directly inhibit either thrombin (Dabigatran, Pradaxa®,) or activated Factor X (rivaroxaban, Xarelto®, and apixaban, Eliquis®) and have been approved for thromboprophylaxis after hip and knee replacement surgery and stroke prevention in non-valvular atrial fibrillation. Moreover, rivaroxaban has been approved for the treatment of deep venous thrombosis, prevention of pulmonary embolism and anticoagulation after acute myocardial infarction. The direct FXa-inhibitor edoxaban (Lixiana®) expects approval for the prevention of stroke in atrial fibrillation in Germany in 2014. Th...
Source: Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS - March 1, 2014 Category: Intensive Care Authors: von Heymann C, Kaufner L, Körber M Tags: Anasthesiol Intensivmed Notfallmed Schmerzther Source Type: research

Dabigatran: patient management in specific clinical settings.
Abstract Dabigatran, a direct thrombin inhibitor, is licensed for the prevention of venous thromboembolism after knee and hip replacement, the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and for the treatment of acute venous thromboembolism. As dabigatran has a favourable benefit-risk profile, it is being increasingly used. Dabigatran differs from vitamin K antagonists as regards its pharmacological characteristics and its impact on certain laboratory tests, and also in the lack of a direct antagonist that can reverse dabigatran-induced anticoagulation. In emergency...
Source: Wiener Klinische Wochenschrift - August 20, 2014 Category: Journals (General) Authors: Kyrle PA, Binder K, Eichinger S, Függer R, Gollackner B, Hiesmayr JM, Huber K, Lang W, Perger P, Quehenberger P, Roithinger FX, Schmaldienst S, Weltermann A, Domanovits H Tags: Wien Klin Wochenschr Source Type: research

Apixaban exerts anti-inflammatory effects in mesangial cells by blocking thrombin/protease-activated receptor-1 system
Atrial fibrillation (AF) is most frequent arrhythmia in patients with chronic kidney disease (CKD) [1,2]. Since diabetes and hypertension are risk components of CHADS2 score and also risk factors for CKD, CKD could affect cardiovascular outcomes in patients with AF [2–5]. Indeed, several papers have shown that renal dysfunction increases the risk of thromboembolic events, stroke and all-cause mortality in AF patients [2–5]. In randomized trials of AF patients with stage III CKD, novel oral anticoagulant, dabigatran 150mg twice daily was superior to warfarin for stroke prevention, while apixaban was superior in regard t...
Source: Thrombosis Research - September 25, 2014 Category: Hematology Authors: Yuji Ishibashi, Takanori Matsui, Sho-ichi Yamagishi Tags: Letter to the Editor-in-Chief Source Type: research

Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients with an elective surgery or procedure. Substudy of the RE-LY trial.
In conclusion, in patients who interrupted dabigatran or warfarin for a surgery/procedure in the RE-LY trial, use of bridging anticoagulation appeared to increase the risk for major bleeding irrespective of dabigatran or warfarin interruption. PMID: 25472710 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 4, 2014 Category: Hematology Authors: Douketis JD, Healey JS, Brueckmann M, Eikelboom JW, Ezekowitz MD, Fraessdorf M, Noack H, Oldgren J, Reilly P, Spyropoulos AC, Wallentin L, Connolly SJ Tags: Thromb Haemost Source Type: research

Practical aspects of treatment with target specific anticoagulants: initiation, payment and current market, transitions, and venous thromboembolism treatment
Abstract Target specific anticoagulants (TSOACs) have recently been introduced to the US market for multiple indications including venous thromboembolism (VTE) prevention in total hip and knee replacement surgeries, VTE treatment and reduction in the risk of stroke in patients with non-valvular atrial fibrillation (NVAF). Currently, three TSOACs are available including rivaroxaban, apixaban, and dabigatran with edoxaban currently under Food and Drug Administration review for VTE treatment and stroke prevention in NVAF. The introduction of these agents has created a paradigm shift in anticoagulation by considerably...
Source: Journal of Thrombosis and Thrombolysis - January 21, 2015 Category: Hematology Source Type: research

Patient-reported health preferences of anticoagulant-related outcomes
This study aimed to use direct measures to elicit patient-reported utilities (i.e., preferences) for anticoagulant-related outcomes. A cross-sectional survey was administered to 100 patients taking warfarin in an anticoagulation clinic. Utilities for six long-term and four short-term anticoagulant-related health states were elicited by the visual analogue scale (VAS) and standard gamble (SG) methods. Health states with the highest SG-derived mean utility values were “well on rivaroxaban” (mean ± SD = 0.90 ± 0.15), “well on warfarin” (0.86 ± 0.17), and “well on dabigatran” (0.83 ± 0.18). Approximat...
Source: Journal of Thrombosis and Thrombolysis - February 11, 2015 Category: Hematology Source Type: research

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20